Clinical Trial Update: A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update indicates ongoing evaluation of the safety, reactogenicity, and immunogenicity of SK Bioscience's Japanese encephalitis mRNA v…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Japanese Encephalitis

Drugs mentioned

• GBP560 (Japanese encephalitis mRNA vaccine)

Snippet

Sponsor: SK Bioscience Co., Ltd. | Conditions: Japanese Encephalitis Virus Disease | Phase 1, Phase 2 | Status: RECRUITING